Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a selective antagonist of the endothelin receptor (ARE) of the propanoic acid group. Indicated in the treatment of idiopathic pulmonary arterial hypertension or associated with connective tissue disease. Single daily dose oral administration.
At the date of the last update, there was no published data available on its excretion in human milk.
Its pharmacokinetic data (high percentage of protein binding and acid pKa) make it unlikely for it to pass into the mothers’ milk in a clinically significant amount.
It is a generally well-tolerated medication with infrequent or serious side effects. (Wei 2016, Frampton 2011)
Its use in Pediatrics is unauthorized.
Until more information is known about this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.